Zobrazeno 1 - 10
of 345
pro vyhledávání: '"Stephen D, Wiviott"'
Autor:
Robert P. Giugliano, MD, SM, Baris Gencer, MD, Stephen D. Wiviott, MD, Jeong-Gun Park, PHD, Charles S. Fuchs, MD, MPH, Wolfram Goessling, MD, PHD, Thomas A. Musliner, MD, Andrew M. Tershakovec, MD, MPH, Michael A. Blazing, MD, Robert Califf, MD, Christopher P. Cannon, MD, Eugene Braunwald, MD
Publikováno v:
JACC. CardioOncology, Vol 2, Iss 3, Pp 385-396 (2020)
Background: An increased risk of malignancy was reported with simvastatin/ezetimibe in 1,873 patients in the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) trial. Objectives: The purpose of this study was to clarify this unexpected finding in a
Externí odkaz:
https://doaj.org/article/e7361de870fb47f0bb0bb5a141f13c54
Autor:
Prakriti Gaba, Michelle L. O’Donoghue, Jeong-Gun Park, Stephen D. Wiviott, Dan Atar, Julia F. Kuder, KyungAh Im, Sabina A. Murphy, Gaetano M. De Ferrari, Zbigniew A. Gaciong, Kalman Toth, Ioanna Gouni-Berthold, Jose Lopez-Miranda, François Schiele, François Mach, Jose H. Flores-Arredondo, J. Antonio G. López, Mary Elliott-Davey, Bei Wang, Maria Laura Monsalvo, Siddique Abbasi, Robert P. Giugliano, Marc S. Sabatine
Publikováno v:
Circulation. 147:1192-1203
Background: Low-density lipoprotein cholesterol (LDL-C) is a well-established risk factor for atherosclerotic cardiovascular disease. However, the optimal achieved LDL-C level with regard to efficacy and safety in the long term remains unknown. Metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::13253a16b49f4776f898e33b3823a98f
https://doi.org/10.1161/circulationaha.122.063399
https://doi.org/10.1161/circulationaha.122.063399
Autor:
Colin Baigent, JonathanR. Emberson, Richard Haynes, William G. Herrington, Parminder Judge, Martin J. Landray, Kaitlin J. Mayne, Sarah Y.A. Ng, David Preiss, Alistair J. Roddick, Natalie Staplin, Doreen Zhu, Stefan D. Anker, Deepak L. Bhatt, Martina Brueckmann, Javed Butler, David Z.I. Cherney, Jennifer B. Green, Sibylle J. Hauske, Hiddo J.L. Heerspink, Silvio E. Inzucchi, Meg J. Jardine, Chih-Chin Liu, Kenneth W. Mahaffey, Finnian R. McCausland, Darren K. McGuire, John J.V. McMurray, Bruce Neal, Brendon L. Neuen, Milton Packer, Vlado Perkovic, Marc S. Sabatine, Scott D. Solomon, Muthiah Vaduganathan, Christoph Wanner, David C. Wheeler, Stephen D. Wiviott, Faiez Zannad
Publikováno v:
The Lancet. 400:1788-1801
Large trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of adverse kidney and cardiovascular outcomes in patients with heart failure or chronic kidney disease, or with type 2 diabetes and high risk of atheroscl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef5c3517816940eed83d96cf1419b14a
https://doi.org/10.1016/s0140-6736(22)02074-8
https://doi.org/10.1016/s0140-6736(22)02074-8
Autor:
Erin A. Bohula, David D. Berg, Mathew S. Lopes, Jean M. Connors, Ijlal Babar, Christopher F. Barnett, Sunit-Preet Chaudhry, Amit Chopra, Wilson Ginete, Michael H. Ieong, Jason N. Katz, Edy Y. Kim, Julia F. Kuder, Emilio Mazza, Dalton McLean, Jarrod M. Mosier, Ari Moskowitz, Sabina A. Murphy, Michelle L. O’Donoghue, Jeong-Gun Park, Rajnish Prasad, Christian T. Ruff, Mohamad N. Shahrour, Shashank S. Sinha, Stephen D. Wiviott, Sean Van Diepen, Mark Zainea, Vivian Baird-Zars, Marc S. Sabatine, David A. Morrow, Kyung Ah Im, Retu Saxena, Brandon Wiley, Carina Benson, Roman Delamed, Nedaa Skeik, Ami Chopra, Marc Judson, Scott Beegle, Boris Shkolnik, Anupama Tiwari, Gregory Wu, Abhijit Raval, Emerald Branch, Franz Rischard, Cameron Hypes, Billie Bixby, Christian Bime, Madhan Sundaram, Nancy Sweitzer, Alfredo Vazquez Sandoval, Heath White, Katherine Berg, Shahzad Shaefi, Michael Donnino, Brett Carroll, Michael Ieong, Kimberly Ackerbauer, Jaime Murphy, Ankeet Bhatt, Alexander Blood, Siddharth Patel, Victor Luu, Shraddha Narechania, Austin Lorganger, Robert Plambeck, Ali Nayfeh, Michael Sanley, Michel Del Cor, AJ Hegg, Winston Nara, Michael Snyder, Faisal Khan, Imad Shawa, Joshua Larned, Elias Collado, Mohammed Al Faiyumi, Rajeev Mehta, Sudarshan Komanapalli, Vijayadershan Muppidi, Mehul Desai, Casey Flanagan, Leonard Genovese, Tariq Haddad, Christopher King, Amber Peterson, Thane Htun, Elizabeth Pionk, Nicolas Mouawad, Chintalapudi Kumar, Kevin Nguyen, Majid Mughal, Ryan Malek, Akarsh Parekh, Christopher Provenzano, Melissa Ianitelli, Nicole Prentice-Gaytan, Adam Bykowski, Don Tait, Shelley Schendel, Varun Yalamanchili, Vasim Lala, Victor Hunyadi, Alexander Papolos, Benjamin Kenigsberg, Aarthi Shenoy, Thomas Stuckey, Douglas McQuaid, Praveen Mannam, Jeffrey McClung, Kent Nilsson, Andrew McKown, Jason Wells, David Hotchkin, Marc Jacobs, Wayne Strauss, Rick Balestra, Vikram Sahni, R. Jeffrey Snell, Hussam Suradi, Sarah Sungurlu, Jessica Kuppy, Eileen Gajo, Foster Adams, Abbas Shehadeh, Addi Suleiman, Harish Nandigam, Jihad Slim, Sardar Ijlal Babar, Dipti Baral, Talha Nawaz, Syed Abdullah Waheed, Randy Roth, Subhas Sitaula, Shahid Hayat, Jooby Babu, Jason Caberto, Victor Hsu, Robert Chang, Markian Bochan, Rafael Garcia-Cortes, Hal Skopicki, On Chen, Lauren Pilato, Paul Richman, Alexander Adler, Praveen Sudhindra, Jamie Beversdorf, Ravindra Kashyap, Parth Mehta, Borna Mehrad, Ali Ataya, Jorge Lascano, Mark Brantly, Adam Austin, Eduard Koman, Thomas Galski, Vijaya Kumar, Ayman Soubani, Nicolas Harrison, Vineet Reddy, Audrey Fonkam
Publikováno v:
Circulation. 146:1344-1356
Background: The efficacy and safety of prophylactic full-dose anticoagulation and antiplatelet therapy in critically ill COVID-19 patients remain uncertain. Methods: COVID-PACT (Prevention of Arteriovenous Thrombotic Events in Critically-ill COVID-19
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f999083149829e3265fcbf720264111
https://doi.org/10.1161/circulationaha.122.061533
https://doi.org/10.1161/circulationaha.122.061533
Autor:
Eri Toda Kato, David A Morrow, Jianping Guo, David D Berg, Michael A Blazing, Erin A Bohula, Marc P Bonaca, Christopher P Cannon, James A de Lemos, Robert P Giugliano, Petr Jarolim, Tibor Kempf, L Kristin Newby, Michelle L O’Donoghue, Marc A Pfeffer, Nader Rifai, Stephen D Wiviott, Kai C Wollert, Eugene Braunwald, Marc S Sabatine
Publikováno v:
European Heart Journal. 44:293-300
Aims Levels of growth differentiation factor 15 (GDF-15), a cytokine secreted in response to cellular stress and inflammation, have been associated with multiple types of cardiovascular (CV) events. However, its comparative prognostic performance acr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4761456818b90545aacae1296b39cca8
https://doi.org/10.1093/eurheartj/ehac577
https://doi.org/10.1093/eurheartj/ehac577
Autor:
Michelle L. O’Donoghue, Robert P. Giugliano, Stephen D. Wiviott, Dan Atar, Anthony Keech, Julia F. Kuder, KyungAh Im, Sabina A. Murphy, Jose H. Flores-Arredondo, J. Antonio G. López, Mary Elliott-Davey, Bei Wang, Maria Laura Monsalvo, Siddique Abbasi, Marc S. Sabatine
Publikováno v:
Circulation. 146:1109-1119
Background: In FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk), the proprotein convertase subtilisin-kexin type 9 inhibitor evolocumab reduced low-density lipoprotein cholesterol (LDL-C) and ris
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbbf9cc5bb13ac2921d8b0595318d0e8
https://doi.org/10.1161/circulationaha.122.061620
https://doi.org/10.1161/circulationaha.122.061620
Autor:
Ofri Mosenzon, Itamar Raz, Stephen D. Wiviott, Meir Schechter, Erica L. Goodrich, Ilan Yanuv, Aliza Rozenberg, Sabina A. Murphy, Thomas A. Zelniker, Anna Maria Langkilde, Ingrid A.M. Gause-Nilsson, Martin Fredriksson, Peter A. Johansson, John P.H. Wilding, Darren K. McGuire, Deepak L. Bhatt, Lawrence A. Leiter, Avivit Cahn, Jamie P. Dwyer, Hiddo J.L. Heerspink, Marc S. Sabatine
Publikováno v:
Diabetes Care, 45(10), 2350-2359. AMER DIABETES ASSOC
OBJECTIVE In patients with moderate to severe albuminuric kidney disease, sodium–glucose cotransporter 2 inhibitors reduce the risk of kidney disease progression. These post hoc analyses assess the effects of dapagliflozin on kidney function declin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3252e685b5257503638587141071cb18
https://doi.org/10.2337/dc22-0382
https://doi.org/10.2337/dc22-0382
Autor:
Brendon L. Neuen, Megumi Oshima, Rajiv Agarwal, Clare Arnott, David Z. Cherney, Robert Edwards, Anna Maria Langkilde, Kenneth W. Mahaffey, Darren K. McGuire, Bruce Neal, Vlado Perkovic, Annpey Pong, Marc S. Sabatine, Itamar Raz, Tadashi Toyama, Christoph Wanner, David C. Wheeler, Stephen D. Wiviott, Bernard Zinman, Hiddo J.L. Heerspink
Publikováno v:
Circulation, 145(19), 1460-1470. LIPPINCOTT WILLIAMS & WILKINS
Background: Hyperkalemia increases risk of cardiac arrhythmias and death and limits the use of renin-angiotensin-aldosterone system inhibitors and mineralocorticoid receptor antagonists, which improve clinical outcomes in people with chronic kidney d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7490f9093dd282190319836f48affdc2
https://doi.org/10.1161/circulationaha.121.057736
https://doi.org/10.1161/circulationaha.121.057736
Autor:
Marc P. Bonaca, Stephen D. Wiviott, David A. Morrow, P. Gabriel Steg, Christian Hamm, Deepak L. Bhatt, Robert F. Storey, Marc Cohen, Julia Kuder, KyungAh Im, Giulia Magnani, Andrzej Budaj, José C. Nicolau, Alexander Parkhomenko, José López‐Sendón, Mikael Dellborg, Rafael Diaz, Frans Van de Werf, Ramón Corbalán, Assen Goudev, Eva C. Jensen, Per Johanson, Eugene Braunwald, Marc S. Sabatine
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 7, Iss 22 (2018)
Background Ticagrelor reduced cardiovascular death, myocardial infarction (MI), or stroke in patients with prior MI in PEGASUS‐TIMI 54 (Prevention of Cardiovascular Events [eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke] in Patie
Externí odkaz:
https://doaj.org/article/03874c11a1de44acb9223300b968ce86
Autor:
Rafael Diaz, Stephen D. Wiviott, Marc S. Sabatine, Jindřich Špinar, Itamar Raz, Assen Goudev, Ofri Mosenzon, Deepak L. Bhatt, Avivit Cahn, Ingrid Gause-Nilsson, Kyong-Soo Park, Darren K. McGuire, Kazuma Oyama, Sabina A. Murphy, Lawrence A. Leiter, John P.H. Wilding, Julia F Kuder
Publikováno v:
European Heart Journal. 43:2958-2967
Aims We investigated the associations between obesity, cardiorenal events, and benefits of dapagliflozin in patients with type 2 diabetes mellitus (T2DM). Methods and results DECLARE–TIMI 58 randomized patients with T2DM and either atherosclerotic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::734b4b400e1aff5ade987e11a2467a4d
https://doi.org/10.1093/eurheartj/ehab530
https://doi.org/10.1093/eurheartj/ehab530